Order results by:
| Issue | Title | |
| Vol 11, No 1 (2015) | EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Andreev, D. A. Sychev | ||
| "... Evaluation of platelet function with subsequent modification of antiplatelet therapy regimen ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... Aim. To study the prevalence of high residual platelet reactivity (HRPR) during the dual ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... ). Material and methods. The evaluation of platelet function in 30 patients with ischemic heart disease ..." | ||
| Vol 10, No 6 (2014) | THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY | Abstract similar documents |
| D. A. Andreev | ||
| "... residual platelet reactivity in patients receiving antiplatelet therapy are considered. The results ..." | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| "... Aim. To estimate the prevalence of atherothrombotic complications depending on platelet ..." | ||
| Vol 2, No 3 (2006) | CLINICAL SIGNIFICANCE OF ASPIRIN RESISTANCE IN PATIENTS WITH CARDIO-VASCULAR DISEASES | Abstract similar documents |
| P. J. Dovgalevsky, N. V. Furman, N. F. Puchinian | ||
| "... results into platelets activation and thrombus formation. Aspirin - one of the most widely used ..." | ||
| Vol 19, No 6 (2023) | Platelet phenotypes and practical aspects of platelet function testing in cardiology | Abstract similar documents |
| Zh. D. Kobalava, A. S. Pisaryuk, A. A. Filkova, E. S. Tukhsanboev, A. A. Boldyreva, D. P. Lazutova, I. A. Meray, M. A. Panteleev | ||
| "... The assessment of platelet dysfunction is usually used by hematologists to diagnose inherited ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... antiplatelet therapy with acetyl salicylic acid and clopidogrel. Numerous clinical characteristics ..." | ||
| Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. V. Rudakova, N. V. Lomakin | ||
| "... Dual antiplatelet therapy, including clopidogrel and aspirin, in a significant share of patients ..." | ||
| Vol 9, No 6 (2013) | ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? | Abstract similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein | ||
| "... The review presents recent data on the usage of platelet functional tests in patients with ischemic ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have ..." | ||
| Vol 4, No 2 (2008) | BETA-ADRENOBLOCKERS AND PLATELET AGGREGATION. CARVEDILOL | Abstract similar documents |
| A. N. Zakirova, F. S. Zarudij, B. N. Garifullin | ||
| "... Approaches evolution to studying of beta-blockers influence on platelet aggregation is reviewed ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... factors in plasma and vessel wall. Antiplatelet drugs do not always provide the necessary antithrombotic ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| "... Aim. To analyze the literary and own data about clopidogrel influence on platelets during ..." | ||
| Vol 4, No 1 (2008) | COMPARISON OF ANTIPLATELET EFFECT AND SAFETY OF ORIGINAL DRUG «ASPIRIN CARDIO» AND GENERIC«ACECARDOL» IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE | Abstract similar documents |
| N. A. Belolipetskiy, S. N. Tolpygina, O. А. Litinskaya, V. G. Belolipetskaya, S. Yu. Martsevich | ||
| "... . Antiplatelet efficacy of ASA medicines were estimated by effects on spontaneous and ADP-induced platelet ..." | ||
| Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
| A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
| "... , and creatinine, complete blood cell count, including platelets number and hemoglobin level. Besides evaluation ..." | ||
| Vol 7, No 5 (2011) | HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY | similar documents |
| G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio | ||
| "... антиагрегантного, но и других биологических эффектов. Цель. Сравнить влияние поддерживающего лечения высокой и ..." | ||
| Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
| "... ,3 y.o. in average). Platelet aggregation was assessed by the Born’s method. Level of arachidonic ..." | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... Prerequisites for the prolonged dual antiplatelet therapy after myocardial infarction are presented ..." | ||
| Vol 20, No 6 (2024) | Platelet reactivity clinical and biochemical markers when taking acetylsalicylic acid as part of dual antiplatelet therapy in the myocardial infarction subacute period | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, A. V. Kapytski | ||
| "... Aim. To study markers that determine residual platelet reactivity in the subacute period ..." | ||
| Vol 6, No 6 (2010) | COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR) | Abstract similar documents |
| S. Yu. Martsevich, S. N. Tolpygina, E. S. Boychenko, R. E. Dubinskaya, Yu. V. Lukina, V. P. Voronina | ||
| "... antiplatelet effect was evaluated by spontaneous and ADP-induced platelet aggregation assessment. Platelet ..." | ||
| Vol 8, No 2 (2012) | EFFICACY AND SAFETY OF ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES | Abstract similar documents |
| S. N. Tolpygina, S. Yu. Martsevich, E. N. Khoseva, N. V. Kiseleva | ||
| "... , as well as ways to improve the safety of antiplatelet therapy are presented, including use of enteric ..." | ||
| Vol 9, No 5 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... двойной антиагрегантной терапии изучали методом телефонного опроса. Результаты. В регистре ПРОГНОЗ ИБС ..." | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... . In addition to endovascular treatment, dual antiplatelet therapy plays a key role in the treatment ..." | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... of clopidogrel’s active metabolite and, respectively, its antiplatelet effect. We sought to determine the impact ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... into the 2nd group (G2). Platelet aggregation was evaluated by Born's method (inducers of platelet ..." | ||
| Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
| V. A. Sulimov, E. V. Moroz | ||
| "... of cardiovascular complications and activity of platelet aggregation, to assess safety of dual antiplatelet therapy ..." | ||
| Vol 7, No 1 (2011) | THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY | Abstract similar documents |
| V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev | ||
| "... half of the patients received the drugs in reverse order. Antiplatelet activity of Plavix and Egitromb ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..." | ||
| Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
| I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
| "... Aim. To study the features of the state of hemostasis and platelet enzymes activity ..." | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... efficiency of present antiplatelet and anticoagulant drugs is shown in the key of preventing PAD thrombotic ..." | ||
| Vol 8, No 4 (2012) | ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin | ||
| "... Alternative approaches to the use of two component antiplatelet therapy in patients with acute ..." | ||
| Vol 17, No 1 (2021) | Aspirin Resistance as a Result of Impaired Interaction of Platelets and Neutrophils in Patients with Coronary Heart Disease | Abstract similar documents |
| M. D. Goncharov, A. A. Savchenko, Yu. I. Grinshtein, I. I. Gvozdev, A. A. Kosinova, T. S. Mongush | ||
| "... ) by platelets and neutrophils in patients with coronary heart disease (CHD) before and after coronary artery ..." | ||
| Vol 8, No 4 (2012) | RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS | similar documents |
| S. R. Willoughby, S. Rajendran, W. P. Chan, N. Procter, S. Leslie, E. A. Liberts, T. Heresztyn, Y. Y. Chirkov, J. D. Horowitz | ||
| "... Prevention Evaluation), были: 1) проверка гипотезы о том, что рамиприл улучшает способность тромбоцитов ..." | ||
| Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
| "... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... antiplatelet therapy (DAT) group. All patients were tested for platelet aggregation using an optical ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| Vol 9, No 3 (2013) | TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN | Abstract similar documents |
| A. I. Martynov, E. V. Akatova, I. V. Urlayeva, O. P. Nicolin | ||
| Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
| "... and combined antiplatelet therapy (acetylsalicylic acid and clopidogrel). Material and methods. 98 patients ..." | ||
| Vol 15, No 3 (2019) | Study of the Association of V640L (rs6133) Polymorphism in the Platelet P-selectin Gene with Acetylsalicylic Acid Resistance in Patients after Coronary Bypass Surgery | Abstract similar documents |
| A. A. Kosinova, T. S. Mongush, M. D. Goncharov, T. N. Subbotina, K. S. Semashchenko, G. Y. Kochmareva, Yu. I. Grinshtein | ||
| "... were confirmed by coronary angiography. The antiplatelet therapy was stopped for at least 5 days before ..." | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... for resistance to antiplatelet therapy with clopidogrel. The decrease in the effectiveness of prolonged therapy ..." | ||
| Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
| O. V. Gaisenok | ||
| "... Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy ..." | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... of antiplatelet and/or anticoagulant drugs is a complicating factor in invasive and surgical procedures ..." | ||
| Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF ACIDUM ACETYLSALICYLICUM USAGE | Abstract similar documents |
| V. N. Drozdov, V. A. Kim | ||
| "... Data about efficacy and safety of acetylsalicylic acid usage as antiplatelet drug and for cancer ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| Vol 13, No 6 (2017) | THIOL ISOMERASES – A POSSIBLE TARGET FOR THROMBOSIS CONTROL | Abstract similar documents |
| I. V. Gribkova, M. V. Davydovskaya | ||
| "... (PDI) serves an essential role in the processes of thrombus formation. PDI is secreted by platelets ..." | ||
| Vol 16, No 3 (2020) | A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study | Abstract similar documents |
| N. V. Lomakin, L. I. Buryachkovskaya, D. A. Zolin, V. I. Kazey | ||
| "... , platelet aggregation in response to arachidonic acid, the concentration of salicylic acid and the level ..." | ||
| Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
| "... 1565C), ITGA2 (C807T), eNOS3 (T786C) genes with high residual platelet reactivity (HRPR) to clopidogrel ..." | ||
| Vol 20, No 4 (2024) | Coagulation disorders in myocardial infarction with nonobstructive coronary arteries | Abstract similar documents |
| A. S. Pisaryuk, A. A. Filkova, E. S. Tukhsanboev, G. S. Svidelskaya, A. A. Ignatova, E. A. Ponomarenko, A. A. Martyanov, A. A. Tarakanova, I. A. Meray, M. A. Panteleev, A. N. Sveshnikova, Z. D. Kobalava | ||
| "... Aim. To investigate the state of the platelet and plasma components of hemostasis in patients ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... value had 71 (68.3%) patients, HAS-BLED≥3 – 33 (31.7%). Only one antiplatelet agent was prescribed to 4 ..." | ||
| Vol 6, No 2 (2010) | EFFECTS OF CARVEDILOL ON PLATELET AGGREGATION IN MEN WITH ST-ELEVATION ACUTE MYOCARDIAL INFARCTION | Abstract PDF (Eng) similar documents |
| A. N. Zakirova, B. N. Garifullin, F. S. Zarudij, N. E. Zakirova | ||
| "... Aim. To study influence of beta-blockers carvedilol and metoprolol tartrate on platelet ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often ..." | ||
| Vol 21, No 2 (2025) | Myocardial infarction and embolism: a rare combination associated with a poor prognosis (a clinical case) | Abstract similar documents |
| O. L. Lyakhovich, O. V. Filyushin, S. S. Yakushin | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called ..." | ||
| Vol 12, No 5 (2016) | Correction of Endothelial Dysfunction in Patients with Essential Hypertension when Using a Combination of Olmesartan/Lercanidipine and Zofenopril/Lercanidipine | Abstract similar documents |
| O. V. Zimnitskaya, M. M. Petrova | ||
| "... combination on the level of soluble platelet-endothelial cell adhesion molecule of the first type (sPECAM-1 ..." | ||
| Vol 4, No 3 (2008) | COMBINED ANTIHYPERTENSIVE THERAPY IN METABOLIC SYNDROME | Abstract similar documents |
| E. I. Mananko, E. A. Bushkova, E. M. Idrisova, A. I. Vengerovsky | ||
| "... metabolism, platelet aggregation in patients with arterial hypertension (HT) and metabolic syndrome (MS ..." | ||
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... Platelets play an important role in the pathogenesis of atherosclerosis. They are involved ..." | ||
| Vol 2, No 2 (2006) | COMPARISON OF EFFECTS OF ENALAPRIL AND UNCONTROLLED ANTIHYPERTENSIVE THERAPY ON INSULIN RESISTANCE, ENDOTHELIUM FUNCTION, MARKERS OF INFLAMMATION AND PLATELET ACTIVITY IN PATIENTS WITH METABOLIC SYNDROME | Abstract similar documents |
| M. N. Mamedov, T. V. Ektova, O. A. Litinskaya, T. Sh. Dzhakhangirov, O. V. Kosmatova | ||
| "... resistance, endothelium function, markers of inflammation, and platelet activity in patients with metabolic ..." | ||
| Vol 8, No 4 (2012) | COMMENTS TO THE PAPER «RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS» | similar documents |
| D. V. Nebieridze | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice. Material and methods ..." | ||
| Vol 5, No 6 (2009) | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky | ||
| "... syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response ..." | ||
| Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
| N. В. Perepech, A. V. Tregubov | ||
| "... Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test ..." | ||
| Vol 15, No 5 (2019) | Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry | Abstract similar documents |
| Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan | ||
| "... of Cardiology (ESC), patients with coexisting AF and ACS should receive dual antiplatelet therapy ..." | ||
| Vol 5, No 5 (2009) | ANTIAGGREGANT THERAPY OVERCOMES LIMITS | Abstract similar documents |
| I. Andreeva | ||
| Vol 6, No 5 (2010) | THE CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY 2010 IN STOCKHOLM: NEWS FOR PRACTITIONERS | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... significant events of the Congress are discussed. Symposia on antiplatelet therapy, hypertension, and recently ..." | ||
| Vol 17, No 4 (2021) | Monitoring of Aspirin Therapy in Patients with Cerebrovascular Pathology | Abstract similar documents |
| M. M. Tanashyan, A. A. Raskurazhev, A. A. Kornilova, A. A. Shabalina, D. A. Abaimov, A. V. Naminov | ||
| "... Aim. Evaluation of various methods for determining the effectiveness of aspirin therapy ..." | ||
| Vol 10, No 3 (2014) | THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER) | Abstract similar documents |
| M. L. Ginzburg, S. Y. Martsevich, N. P. Kutishenko, Y. V. Lukina, A. D. Deev | ||
| "... receiving b-blockers, 35.3% - renin-angiotensin-aldosterone system (RAAS) inhibitors, 15.7% - antiplatelet ..." | ||
| Vol 9, No 2 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER. (Part 1) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... of cardiovascular complications (antiplatelets, β-blockers, ACE inhibitors, statins) were not often prescribed ..." | ||
| Vol 6, No 1 (2010) | ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... therapy (TAT), selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet ..." | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern therapy of atherosclerosis ..." | ||
| Vol 8, No 6 (2012) | THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS | Abstract similar documents |
| S. Yu. Martsevich, M. L. Gynzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. U. Drozdova, E. V. Daniels, A. V. Fokina | ||
| "... reference AMI only a small number of the patients received the main drug groups (antiplatelet agents, β ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... of action and clinical efficiency of antithrombotic and antiplatelet medicines such as acetylsalicylic acid ..." | ||
| Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
| I. N. Bokarev, L. V. Popova | ||
| "... is highlighted. ASA modes of action and its position among the modern antiplatelet agents are considered ..." | ||
| Vol 15, No 3 (2019) | Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities | Abstract similar documents |
| article Editorial | ||
| "... of both coagulation and platelet). Experts noted that combination of rivaroxaban 2.5 mg BID ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| "... to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings ..." | ||
| Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
| "... Aim. To evaluate an adequacy of dual antiplatelet therapy (DAPT) in patients with acute coronary ..." | ||
| Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
| K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
| "... antiplatelet drugs (acetylsalicylic acid and clopidogrel) and heparin. There were not any reasons ..." | ||
| Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
| E. N. Dankovtseva, D. A. Zateyshchikov | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| "... recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83 ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT ..." | ||
| Vol 13, No 2 (2017) | TREATMENT CHARACTERISTICS OF ACUTE CORONARY SYNDROME IN ELDERLY PATIENTS: PRACTICE OF N.I. PIROGOV CITY CLINICAL HOSPITAL №1 | Abstract similar documents |
| M. Yu. Gilyarov, M. O. Zheltoukhova, E. V. Konstantinova, M. D. Muksinova, L. S. Muradova, A. P. Nesterov, A. E. Udovichenko | ||
| "... syndrome (ACS) with existing guidelines and evaluation of ACS features during the last two years of working ..." | ||
| Vol 12, No 3 (2016) | CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH ISCHEMIC HEART DISEASE RESISTANT TO ACETYLSALICYLIC ACID IN PERIOPERATIVE PERIOD OF CORONARY ARTERY BYPASS GRAFT: RESULTS OF AN OPEN PROSPECTIVE STUDY | Abstract PDF (Eng) similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein, A. V. Kovalev, V. G. Sukhovol'skiy, A. A. Savchenko | ||
| "... in enteric form at a dose of 100 mg. To determine the sensitivity to ASA platelet aggregation induced ..." | ||
| Vol 14, No 6 (2018) | Evaluation of Drug Therapy and Adherence to It in Patients after Acute Coronary Syndrome in Real Clinical Practice (Results of One Year Observation) | Abstract PDF (Eng) similar documents |
| L. A. Khaisheva, S. E. Glova, V. A. Suroedov, A. S. Samakaev, S. V. Shlyk | ||
| "... was maximal for ACE inhibitors/angiotensin receptor blockers (83.6%), dual antiplatelet therapy (79.9%) and β ..." | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... of revealed disorders with antiplatelet agent — clopidogrel 75 mg/day. Material and methods. 40 patients ..." | ||
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well ..." | ||
| Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
| S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
| "... in angioplasty with stenting were found. Patients before ACS in 2014 received less antiplatelet agents than ..." | ||
| Vol 13, No 5 (2017) | INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION | Abstract similar documents |
| E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash | ||
| "... of acetylsalicylic acid (100 mg/day) and ticagrelor 90 mg twice a day. ADP-induced platelet aggregation (1.25 and 2 ..." | ||
| Vol 8, No 5 (2012) | THE LIS STUDY (LYUBERTSY STUDY OF MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION). EVALUATION OF THE PHARMACOTHERAPY. PART 1. TREATMENT OF PATIENTS BEFORE MYOCARDIAL INFARCTION AND ITS INFLUENCE ON HOSPITAL MORTALITY RATE | Abstract similar documents |
| S. Y. Marcevich, M. L. Ginzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. Y. Drozdova, E. V. Danijel's, A. V. Fokina | ||
| "... -blockers, 35.3% — ACE inhibitors, 15.7% — antiplatelet drugs, 1.9% — statins. Reduction in the hospital ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , in rational pharmacotherapy in cardiology was shown on the example of its substrates – digoxin, antiplatelet ..." | ||
| Vol 14, No 2 (2018) | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. В. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, K. O. Tsukanova | ||
| "... in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74 ..." | ||
| Vol 17, No 2 (2021) | Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic | Abstract similar documents |
| S. M. Mamatov, B. Kanat kyzy, A. O. Musakeev, N. K. Kinderbaeva, T. J. Tagaev | ||
| "... , antiplatelet agents - 196 (50.6%), no therapy - 24 (6.2%). Anticoagulant therapy in 153 patients included ..." | ||
| Vol 9, No 2 (2013) | ANTITHROMBOTIC THERAPY SAFETY MONITORING BASED ON SPONTANEOUS REPORTS | Abstract similar documents |
| O. V. Shatalova, O. N. Smuseva, A. S. Maslakov | ||
| "... .2% (4/18), and antiplatelet drugs 11.1% (2/18). Conclusion. Warfarin was more often cause of ADR during ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... the need of dual antiplatelet agents therapy. ..." | ||
| Vol 9, No 3 (2013) | EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA) | Abstract similar documents |
| , , , , , , , , , , , | ||
| "... и методы. Проведенное исследование TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With ..." | ||
| Vol 19, No 1 (2023) | Arterial Hypertension and Severe COVID-19 in Hospitalized Patients: Data from a Cohort Study | Abstract PDF (Eng) similar documents |
| V. I. Podzolkov, A. E. Bragina, A. I. Tarzimanova, L. V. Vasilyeva, E. S. Ogibenina, E. E. Bykova, I. I. Shvedov, A. A. Ivannikov, N. A. Druzhinina | ||
| "... protein and decreased platelet count were independently associated with mortality, hypertension having ..." | ||
| 1 - 100 of 317 Items | 1 2 3 4 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
